INTARCIA
Intarcia Therapeutics, Inc.
Application Filed: 2017-01-31
Trademark Application Details
THIRD EXTENSION - GRANTED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87319506 |
| Registration Number | 6175490 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Maury M. Tepper, III |
| Law Office Assigned | M30 |
| Employee Name | MARTIN, LIEF ANDREW |
Timeline
| 2017-01-31 | Application Filed |
| 2017-12-19 | Published for Opposition |
| 2018-07-26 | Location: INTENT TO USE SECTION |
| 2019-08-11 | Status: Live/Pending |
| 2019-08-13 | Transaction Date |
| 2020-10-13 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  Intarcia Therapeutics, Inc. |
| Address | Suite 1300 One Marina Park Drive Boston DE 02210 |
| Legal Entity Type | Corporation |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 10 |
| U.S. Codes: | 026,039,044 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations, namely, hormone analogues; drug delivery devices filled with pharmaceutical preparations for the treatment of diabetes, obesity and metabolic disorders; pharmaceutical preparations for the treatment of diabetes, obesity and metabolic disorders; medical diagnostic reagents for in vivo use |
| GS0421 | Scientific, pharmaceutical and medical research and development services; Research design and testing services for the research development of products in the fields of pharmaceuticals, biopharmaceuticals, science, medicine and drug delivery systems; research and development of new clinical products, drugs, pharmaceuticals and drug delivery systems and devices; and development of pharmaceutical preparations, products and technology in the fields of diabetes, obesity, metabolic diseases/disorders, drug delivery technologies, and administration of pharmaceuticals; medical research; design and testing of new products, technologies and therapies in the fields of diabetes, obesity, metabolic diseases/disorders, drug delivery technologies, and administration of pharmaceuticals |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2017-02-03 | 1 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2017-04-26 | 2 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2017-04-27 | 3 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2017-04-27 | 4 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2017-04-27 | 5 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2017-10-27 | 6 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2017-10-27 | 7 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2017-10-27 | 8 TEME I:Incoming Correspondence |
| EXAMINERS AMENDMENT -WRITTEN | 2017-11-07 | 9 CNEA R:Renewal |
| EXAMINERS AMENDMENT E-MAILED | 2017-11-07 | 10 GNEA O:Outgoing Correspondence |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2017-11-07 | 11 GNEN O:Outgoing Correspondence |
| EXAMINER'S AMENDMENT ENTERED | 2017-11-07 | 12 XAEC I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2017-11-07 | 13 CNSA P: |
| ASSIGNED TO LIE | 2017-11-15 | 14 ALIE A:Allowance for Publication |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2017-11-29 | 15 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2017-12-19 | 16 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2017-12-19 | 17 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2018-02-13 | 18 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2018-07-19 | 19 EEXT I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2018-07-26 | 20 AITU A:Allowance for Publication |
| EXTENSION 1 FILED | 2018-07-19 | 21 EXT1 S: |
| EXTENSION 1 GRANTED | 2018-07-26 | 22 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-07-27 | 23 EXRA E:E-Mail |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2018-09-05 | 24 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2018-09-05 | 25 ARAA I:Incoming Correspondence |
| TEAS EXTENSION RECEIVED | 2019-02-11 | 26 EEXT I:Incoming Correspondence |
| EXTENSION 2 FILED | 2019-02-11 | 27 EXT2 S: |
| EXTENSION 2 GRANTED | 2019-02-11 | 28 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-02-13 | 29 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2019-08-11 | 30 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2019-08-11 | 31 EXT3 S: |
| EXTENSION 3 GRANTED | 2019-08-11 | 32 EX3G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-08-13 | 33 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2020-02-06 | 34 EEXT I:Incoming Correspondence |
| EXTENSION 4 FILED | 2020-02-06 | 35 EXT4 S: |
| EXTENSION 4 GRANTED | 2020-02-06 | 36 EX4G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-02-08 | 37 EXRA E:E-Mail |
| TEAS STATEMENT OF USE RECEIVED | 2020-08-12 | 38 EISU I:Incoming Correspondence |
| USE AMENDMENT FILED | 2020-08-12 | 39 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2020-08-13 | 40 SUPC I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2020-09-04 | 41 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2020-09-05 | 42 SUNA E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2020-10-13 | 43 R.PR A:Allowance for Publication |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 